(Q36699460)

15 August 2017

0 references

Access to high cost medicines in Australia: ethical perspectives (English)

1 reference

15 August 2017

0 references

0 references

1 reference

Ric Day

4

0 references

author name string

Christine Y Lu

series ordinal

1

1 reference

15 August 2017

Paul Macneill

series ordinal

2

1 reference

15 August 2017

Ken Williams

series ordinal

3

1 reference

15 August 2017

19 May 2008

1 reference

Australia and New Zealand Health Policy

15 August 2017

1 reference

15 August 2017

5

1 reference

15 August 2017

4

1 reference

Creative Commons Attribution 2.0 Generic

15 August 2017

start time

19 May 2008

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2412887

The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2412887

Accessing health outcome data on high-cost medicines in Australia.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2412887

Recent developments in targeting access to high cost medicines in Australia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2412887

Evidence based medicine guidelines: a solution to rationing or politics disguised as science?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2412887

Ethical issues of cost effectiveness analysis and guideline setting in mental health care

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2412887

The Australian National Medicinal Drug Policy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2412887

Ethics and evidence based medicine

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2412887

Evidence based medicine and ethics

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2412887

Accountability for reasonableness

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2412887

Health policy approaches to measuring and valuing human life: conceptual and ethical issues.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2412887

Toward ethical review of health system transformations.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2412887

Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: are we on target?

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2412887

Tailoring access to high cost, genetically targeted drugs.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2412887

Access to high cost drugs in Australia

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2412887

Evidence-based medicine as an instrument for rational health policy.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2412887

The ethics of Pharmaceutical benefit management.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2412887

Subsidised access to TNF-alpha inhibitors: is the rationale for exclusion of rheumatoid-factor-negative patients defensible?

5 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18489760

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Subsidised access to TNF alpha inhibitors: is the rationale for exclusion of rheumatoid-factor-negative patients defensible?

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18489760

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The subsidy of pharmaceuticals in Australia: processes and challenges

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18489760

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1743-8462-5-4

1 reference

Dimensions Publication ID

15 August 2017

0 references

1 reference

15 August 2017

PubMed publication ID

18489760

1 reference